Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma

PURPOSE: Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexes. In a preclinica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Beasley, Georgia M., Riboh, Jonathan C., Augustine, Christina K., Zager, Jonathan S., Hochwald, Steven N., Grobmyer, Stephen R., Peterson, Bercedis, Royal, Richard, Ross, Merrick I., Tyler, Douglas S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4668281/
https://ncbi.nlm.nih.gov/pubmed/21343562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.1224
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados